27, 2015 /PRNewswire/ -- Biopharmaceuticals
are medicinal drugs which are produced through biotechnology methods such as recombinant DNA techniques, fermentation, hybridoma techniques, and purification processes.
Contract Manufacturing Market, 2015 - 2025' report provides an extensive study of the contract manufacturing market for biopharmaceuticals
BioPartners, Baar, Switzerland, a privately-owned biopharmaceuticals
company has expressed disappointment that its biosimilar Interferon Alpha, Alpheon(R), had received a negative opinion from the European Medicines Agency's Committee on Medicinal Products for Human Use (CHMP).
As consumers are deepening their understanding of types and efficacies of biopharmaceuticals
, in vitro diagnostic reagent products are slowly approaching the families, and genetic engineering drugs and antibody drugs are also gradually replacing part of chemical carcinoma drugs with strong side effects, thus greatly benefiting the treatment of cancer patients.
This report analyzes the worldwide markets for Biopharmaceuticals
in US$ Million by the following Segments: Recombinant Protein, Monoclonal Antibodies (mAbs), Insulin, and Vaccines.
During the past five years, estimates for biopharmaceuticals
have varied widely as analysts and producers have juggled the promise of new drugs with the technological and financial risks of manufacturing them efficiently.
China's demand for Biopharmaceuticals
has grown at a fast pace in the past decade.
Chart 24: Glance at 2006, 2010 and 2015 Global Oncology Market Share (%) of Biopharmaceuticals
by Geographic Region - North America, Western Europe, Asia-Pacific and Rest of World
The report provides an analysis of biopharmaceuticals
approved in 2010 and 2011, operating dynamics in the biopharmaceutical
industry, the current scenario in biopharmaceutical
manufacturing, key stakeholders, the current market size (2011) of biopharmaceuticals
, and forecasts to 2016 for India, China, South Korea and the global market.
Biovest is a majority owned subsidiary of Accentia Biopharmaceuticals
LONDON -- Morria Biopharmaceuticals
Plc, a biopharmaceutical
company focusing on novel, non-steroidal anti-inflammatory drugs, announced today the publication of results from its human pilot clinical trial on its leading topical Multi-Functional Anti Inflammatory Drug (MFAID) MRX1.
Single-use disposable technique for biopharmaceuticals
and stringent environmental regulations are some of the key factors driving demand for membrane technology in pharmaceutical, biopharmaceutical
and life sciences industries.